Introduction {#s1}
============

*Escherichia coli* (*E. coli*) is both a ubiquitous commensal bacterium in intestinal tract and an important pathogen of diarrhea or extraintestinal infections of humans and animals, and both commensal and pathogenic isolates usually share the same environment (Wu et al., [@B42]). Cephalosporins are effective for gram-negative bacterial infections, especially for infections caused by multidrug resistant (MDR) *E. coli* (Silva-Sanchez et al., [@B31]). At present, extended-spectrum β-lactams are not the first-line treatment in food animals, whereas the resistance to β-lactams, especially to the third- and fourth-generation cephalosporins has increased markedly accompanying their massive or inappropriate use over the past decades, and it is also considered as an important public health challenge (Agersø and Aarestrup, [@B1]). Nowadays, one of the most worrisome resistance mechanisms to β-lactams is the emergence of extended-spectrum β-lactamases (ESBLs), which could inactivate oxyimino-β-lactams like third-generation cephalosporins and aztreonam (Liu et al., [@B19]). Moreover, ESBLs are generally located on the transmissible plasmids, and could be acquired between bacteria by conjugation mechanism (Cantas et al., [@B6]). A recent study has further suggested that ESBL-producing *E. coli* isolate, along with their antibiotic resistance genes, can spread from food animals and animals-derived foods to humans via food-chain (Geser et al., [@B11]). Additionally, plasmid-mediated AmpC β-lactamase *bla*~CMY−2~, carbapenemases *bla*~NDM−1~, *bla*~OXA−48~ and *bla*~KPC−2~ are also increasingly described (Conceição-Neto et al., [@B9]; Subirats et al., [@B33]). As a result, the dissemination of ESBL-producing isolates poses a serious risk to both animal and human health. Furthermore, ESBL producers have been associated with resistance to non-β-lactam antimicrobials, such as fluoroquinolones, aminoglycosides and sulfonamides, which are often used long term to treat and prevent diseases on pig farms in China (Tian et al., [@B36], [@B35]; Yuan et al., [@B45]). Especially, plasmid-mediated quinolone resistance (PMQR) genes are thought to be linked with ESBL production, and spread of *E. coli* co-expressing PMQRs and ESBLs could contribute to growing concerns about resistant *E. coli* isolates (Wang et al., [@B40]).

The prevalence of ESBL-producing *E. coli* isolates in food animals has been increasing worldwide, and they pose a serious challenge in controlling bacterial diarrhea in swine industry. However, very little data have been reported on the occurrence and various types of β-lactamases among *E. coli* from swine in Northwest China. The main purpose of this study was to screen ESBL-producing *E. coli* isolates collected from pig farms in Northwest China, and further analyze ESBL producers based on genetic relatedness, virulence profiles, and the occurrence and transferability of β-lactamase and PMQR genes.

Materials and methods {#s2}
=====================

Sample collection and bacterial culture
---------------------------------------

During May 2015 to June 2017, 456 *E. coli* isolates (270 from healthy pigs, 186 from diarrheal pigs) were isolated from fecal samples of different swine in ten pig farms, which are widely dispersed across Shaanxi and Gansu provinces. Fecal samples were collected from individual pigs using a sterile cotton swab and transported to laboratory within 12 h. All samples were immediately seeded on MacConkey agar (Beijing Land Bridge Technology Co., Ltd, Beijing, China). After incubation at 37°C for 18 to 24 h, three colonies with typical *E. coli* morphology (bright pink with a dimple) were randomly selected and transferred to Eosin Methylene Blue agar (Qingdao Hope Bio Technology Co., Ltd, Qingdao, Shandong, China) for further purification. Finally, the suspect *E. coli* isolates on Eosin Methylene Blue agar (green colonies with a metallic sheen) were subjected to biochemical tests (indole, methyl red, oxidase, citrate, and triple sugar iron) as described previously (Liu et al., [@B22]). All confirmed *E. coli* isolates were stored at −80°C in Tryptic Soy broth medium containing 30% glycerol for later study.

Antimicrobial susceptibility testing
------------------------------------

The minimum inhibitory concentrations (MICs) of ampicillin, amoxicillin-clavulanic acid, ceftiofur, cefotaxime, ceftrizxone, ceftazidime, meropenem, enrofloxacin, ciprofloxacin, florfenicol, sulfamethoxazole/trimethoprim, gentamicin, amikacin, oxytetracycline, and colistin were determined by a standardized microdilution method following CLSI guidelines (CLSI, [@B8]). All MIC determinations were performed in triplicate, with *E. coli* ATCC 25922 serving as a quality control. Meanwhile, double-disk diffusion method was used to screen for the ESBL production among all isolates with cefotaxime and ceftazidime alone and in combination with clavulanic acid by using the guidelines recommended by CLSI ([@B8]). Initial screening analyses indicated that 44 (9.6%) *E. coli* isolates were identified as phenotypic ESBL producers, which were further investigated for molecular characterization.

Phylogenetic grouping and virulence genotyping
----------------------------------------------

DNA from each ESBL producer was extracted using boiling method, and the distribution of phylogenetic groups of ESBL producers were determined by quadruplex PCR as described by Clermont et al. (Clermont et al., [@B7]). Meanwhile, enterotoxins (*elt, estA, estB, stx1, stx2*, and *astA*) and fimbrial adhesins (F4, F5, F6, F17, F18 and F41) as well as intimin encoded by *eae* gene were detected using single or multiplex PCR with specific primers as previously described (Boerlin et al., [@B4]; Toledo et al., [@B37]). The *E. coli* strains used as positive controls were B2 (*eae, stx1, stx2*), 256 (*estA, estB*), 281 (*elt*), G2077 (F4), B21523 (F5), J7203349 (F6), 320 (F41), and B37429 (F18), and *E. coli* K12 C600 was used as a negative control. Part of control strains were kindly supplied by Dr. Boothe (Auburn University, USA). The primer sequences used for PCR detection are listed in Table [S1](#SM1){ref-type="supplementary-material"}.

Identification of β-lactamase genes and plasmid-mediated quinolone resistance genes
-----------------------------------------------------------------------------------

The occurrence of β-lactamase genes (*bla*~TEM~, *bla*~SHV~, *bla*~CTX−Ms~), plasmid-mediated AmpC β-lactamase (*bla*~CMY−2~) and carbapenemase genes (*bla*~KPC−2~, *bla*~NDM−1~, and *bla*~OXA−48~) among ESBL producers were determined by PCR and sequencing using specific primers (Table [S2](#SM2){ref-type="supplementary-material"}). The PCR products were purified using a PCR Purification Kit (TianGen, Beijing, China), and then the amplified products were sequenced by Sangon Biotech (Shanghai, China). DNA Sequences were compared with known sequences available from the BLAST program (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) (Altschul et al., [@B2]). Additionally, all ESBL producers were screened for the presence of PMQR genes (*qnrA, qnrB, qnrC, qnrD, qnrS, aac(6\')-Ib-cr, oqxAB*, and *qepA*) as described previously (Liu et al., [@B20]; Xu et al., [@B44]). *E. coli* J53 strains containing pMG252, pMG298, pMG306, and pMG298 were used as positive controls for *qnrA, qnrB, qnrS*, and *aac(6*′*)-Ib-cr* genes, respectively. *E. coli* J7261205 (pSTVqepA) and S5314175 were included as positive controls for *qepA* and *oqxAB*, respectively. The positive control strain for *qnrC* was not available.

Conjugation experiments
-----------------------

In order to analyze the horizontal transferability of β-lactamase and PMQR genes, especially *bla*~OXA−48~ gene, conjugation experiments were performed with eight ESBL-producing *E. coli* isolates, including four *bla*~OXA−48~ positive isolates, from different pig farms in seven different regions. Conjugation experiments were conducted by broth mating method using *E. coli* J53 AZ^r^ as a recipient (Shaheen et al., [@B30]). Transconjugants were selected on Tryptic Soy agar plates containing sodium azide (150 μg/ml) and cefotaxime (2 μg/ml). All transconjugants, recipient and donors were subjected to antimicrobial susceptibility testing. PCR and sequencing were performed to verify the transferability of PMQR and β-lactamase genes.

Multilocus sequence typing (MLST)
---------------------------------

MLST of ESBL-producing *E. coli* isolates was performed as described previously (Wirth et al., [@B41]). A detailed scheme of gene amplification, allelic type and sequence type assignment methods is available on the MLST website (<http://mlst.warwick.ac.uk/mlst/dbs/Ecoli>).

Statistical analysis
--------------------

Significance was determined by Pearson\'s Chi-squared test with Yates continuity correction using "R" software (version 3.0.1), and the level of significance was set at *P* \< 0.05.

Results {#s3}
=======

Antimicrobial susceptibility of *E. coli* isolates
--------------------------------------------------

The results of antibiotic resistance profiles of 456 *E. coli* isolates are listed in Table [1](#T1){ref-type="table"}, 96.1% of the *E. coli* isolates were resistant to ampicillin, followed by amoxicillin-clavulanic acid (91.2%), sulfamethoxazole/trimethoprim (82%), oxytetracycline (74.3%), enrofloxacin (70%), gentamicin (61.4%), florfenicol (58.8%), ciprofloxacin (57.9%), and amikacin (52.2%). The percentage of resistance to other antibacterial agents were lower than 50%. It is noteworthy that significantly more *E. coli* isolates from diarrheal pigs than those from healthy pigs were resistant to most antimicrobials tested (*P* \< 0.001) with the exception of ampicillin, sulfamethoxazole/trimethoprim and colistin (Table [1](#T1){ref-type="table"}). Of 456 *E. coli* isolates investigated, 44 isolates (9.6%, six isolates from healthy pigs and 38 from diarrhea pigs) were confirmed as phenotypic ESBL producers, and exhibited MDR phenotype. 97.7% of the ESBL producers were resistant to ampicillin, followed by oxytetracycline (93.2%), amoxicillin-clavulanic acid (93.2%), enrofloxacin (93.2%), sulfamethoxazole/trimethoprim (90.9%), ceftazidime (86.4%), cefotaxime (84.1%) and gentamicin (81.8%).

###### 

Antibiotic resistance profiles of *E. coli* isolates from swine in Northwest China.

  **Antimicrobials**   **Number of resistant isolates (%)**   ***E. coli*** **isolates from healthy pigs (*****n*** = **270)**   ***E. coli*** **isolates from diarrheal pigs (*****n*** = **186)**   **ESBL-producing isolates (n** = **44)**   ***P*-value Isolates from healthy pigs *vs*. Isolates from diarrheal pigs/ESBL-producing isolates**                                                                              
  -------------------- -------------------------------------- ------------------------------------------------------------------ -------------------------------------------------------------------- ------------------------------------------ ----------------------------------------------------------------------------------------------------- ------------ ----------- ------- ----- ---------- ---------- ------- ----- ----------
  Ampicillin           438(96.1)                              1--256                                                             252(93.3)                                                            64                                         256                                                                                                   1--\>512     186(100)    256     512   4--\>512   43(97.7)   256     512   \>0.05
  Amoxicillin          416(91.2)                              1--512                                                             238(88.1)                                                            32                                         256                                                                                                   1--\>512     178(95.7)   128     512   1--\>512   41(93.2)   256     512   \< 0.01
  Ceftiofur            177(38.8)                              0.063--64                                                          56(20.7)                                                             0.5                                        16                                                                                                    1--512       121(65.1)   64      128   2--512     32(72.7)   128     256   \< 0.001
  Cefotaxime           184(40.4)                              0.25--128                                                          51(18.9)                                                             0.25                                       32                                                                                                    0.5--512     133(71.5)   64      256   1--512     37(84.1)   128     256   \< 0.001
  Ceftazidime          188(41.2)                              0.5--256                                                           58(21.5)                                                             2                                          32                                                                                                    2--512       130(69.9)   322     256   2--512     38(86.4)   64      256   \< 0.001
  Ceftrizxone          165(36.2)                              0.125--128                                                         48(17.8)                                                             0.52                                       32                                                                                                    0.5--512     117(62.9)   64      128   1--512     30(68.2)   128     256   \< 0.001
  Meropenem            3(0.7)                                 0.03--4                                                            0(0)                                                                 0.125                                      0.5                                                                                                   0.03--16     3(1.6)      0.25    1     0.03--16   3(6.8)     0.25    1     \< 0.01
  Enrofloxacin         319(70)                                0.125--256                                                         150(55.6)                                                            16                                         64                                                                                                    0.063--512   169(90.9)   128     512   2--512     41(93.2)   128     512   \< 0.001
  Ciprofloxacin        264(57.9)                              0.063--128                                                         128(47.4)                                                            8                                          32                                                                                                    0.063--512   136(73.1)   64      256   1--512     33(75)     128     256   \< 0.001
  Florfenicol          268(58.8)                              1--256                                                             124(45.9)                                                            16                                         64                                                                                                    8--\>512     144(77.4)   256     512   8--\>512   35(79.5)   256     512   \< 0.001
  Gentamicin           280(61.4)                              0.125--128                                                         134(49.6)                                                            16                                         128                                                                                                   0.5--512     146(78.5)   64      256   4--512     36(81.8)   128     256   \< 0.001
  Amikacin             238(52.2)                              0.063--64                                                          121(44.8)                                                            8                                          64                                                                                                    0.063--512   117(62.9)   64      256   4--512     31(70.5)   128     256   \< 0.001
  Oxytetracycline      339(74.3)                              1--512                                                             169(62.6)                                                            32                                         256                                                                                                   1--\>512     170(91.4)   256     512   2--\>512   41(93.2)   256     512   \< 0.001
  Colistin             1(0.2)                                 0.03--0.5                                                          0(0)                                                                 0.03                                       0.125                                                                                                 0.063--8     1(0.5)      0.125   0.5   0.063--8   1(2.3)     0.125   0.5   \>0.05
  Sulfamethoxazole     374(82)                                0.25--256                                                          214(79.3)                                                            64                                         256                                                                                                   1--512       160(86.0)   32      256   2--512     40(90.9)   128     256   \>0.05

Phylogenetic typing and virulence genotyping
--------------------------------------------

Phylogenetic group analysis for 44 ESBL producers revealed that the predominant phylogenetic group was D (14/44, 31.8%), followed by phylogenetic groups B2 (11/44, 25%), A (9/44, 20.5%), B1 (6/44, 13.6%), C (3/44, 6.8%), and E (1/44, 2.3%) (Table [2](#T2){ref-type="table"}). Groups D and B2 accounted for 56.8% of the ESBL producers. The frequencies of major virulence genes are listed in Table [2](#T2){ref-type="table"}. 93.2% of the ESBL producers possessed at least one virulence gene. *estA* (*n* = 18) was the most prevalent toxin gene, followed by *estB* (*n* = 15), *astA* (*n* = 12), and *elt* (*n* = 10) genes. The most prevalent fimbrial adhesin was F4 (*n* = 18), followed by F18 (*n* = 10), F17 (*n* = 4), F5 (*n* = 3), F6 (*n* = 3) and F41 (*n* = 2). Furthermore, 86.4% (38/44) of the ESBL producers carried both enterotoxins and fimbrial adhesins, and 27 different virotypes were identified according to the combinations of enterotoxin and adhesin genes. The *eae* gene was detected in two ESBL producers (4.5%), while *stx1* and *stx2* were not detected.

###### 

Extended-spectrum β-lactamase-producing *E. coli* isolates from swinein Northwest China.

  **Isolate ID**   **Phylogentic group**   **Sources**     **MLST**   **Resistance profiles**                                   **β-lactamase genes**                        **PMQR genes**                             **Virulence genes**
  ---------------- ----------------------- --------------- ---------- --------------------------------------------------------- -------------------------------------------- ------------------------------------------ ---------------------
  FF170322         A                       Diarrheal pig   ST10       AMP AMC EFT CAZ CEX OTC ENR CIP FFC SXT                   TEM-1, CTX-M-9, CTX-M-123                    *qnrA, qnrB, qepA, oqxAB*                  *estA, astA*,F18
  JY160633         A                       Healthy pig     ST10       AMP AMC CAZ ENR CIP FFC OTC GEN                           TEM-1, CTX-M-9, CTX-M-123                    *qnrS, aac(6\')-Ib-cr*                     *estA*, F17
  FP170743         A                       Diarrheal pig   ST10       AMP AMC EFT CTX CEX ENR CIP FFC OTC SXT                   TEM-1, CTX-M-14, CTX-M-123                   *qnrS, qnrA*                               *estB*, F18
  FP170756         A                       Diarrheal pig   ST10       AMP AMC EFT CTX CAZ CEX ENR CIP FFC OTC GEN AMK SXT       TEM-1, CTX-M-15                              *qnrS, qnrA*                               *astA*, F5
  MX161024         A                       Diarrheal pig   ST10       AMP AMC EFT CAZ ENR CIP FFC OTC GEN AMK SXT               TEM-1, CTX-M-15                              *qnrA*                                     *astA*, F4
  HX160912         A                       Diarrheal pig   ST167      AMP AMC CTX ENR SXT                                       TEM-1, CTX-M-64                              *qnrS, qnrA*                               *estA*, F17
  JY160509         A                       Healthy pig     ST175      AMP CTX CEX OTC CAZ GEN SXT                               TEM-1,CTX-M-14                               *qnrA*                                     *estA*, F4
  FP160935         A                       Healthy pig     ST2715     AMP AMC CAZ ENR CIP OTC SXT                               SHV-12                                       \-                                         \-
  JY170618         A                       Diarrheal pig   ST5236     AMP AMC CTX CAZ FFC GEN AMK OTC                           TEM-1, CTX-M-14                              *qnrA*                                     *estA*, F18
  HX160826         B1                      Diarrheal pig   ST75       AMP CAZ CEX ENR FFC OTC                                   TEM-1, CTX-M-14                              *qnrS*                                     *estA*, F17
  ZZ160931         B1                      Healthy pig     ST155      AMP AMC CTX CAZ OTC GEN AMK SXT                           TEM-1, CTX-M-64                              \-                                         \-
  ZZ170521         B1                      Diarrheal pig   ST183      AMP AMC CTX CAZ ENR OTC SXT                               TEM-1, CTX-M-14                              *qnrA*                                     *estA, astA*, F6
  FP170723         B1                      Healthy pig     ST302      AMC CAZ OTC ENR FFC                                       CTX-M-123                                    \-                                         \-
  JY170327         B1                      Diarrheal pig   ST355      AMP CAZ OTC ENR SXT                                       TEM-1, CTX-M-14                              *qnrS*                                     *eae*
  FF170327         B1                      Healthy pig     ST443      AMP AMC CAZ CEX ENR OTC SXT                               CTX-M-14                                     *qnrS, aac(6\')-Ib-cr*                     *astA*
  HX161021         B2                      Diarrheal pig   ST29       AMP AMC EFT CTX CAZ ENR CIP FFC OTC GEN AMK SXT           CTX-M-14, CTX-M-123                          *qnrB, aac(6\')-Ib-cr*                     *estA*, F4
  FF170425         B2                      Diarrheal pig   ST95       AMP AMC EFT CTX CAZ CEX ENR CIP FFC OTC GEN AMK SXT       TEM-1, CTX-M-15, CTX-M-64                    \-                                         *astA*, F18
  MX160918         B2                      Diarrheal pig   ST104      AMP AMC EFT CTX CEX OTC ENR CIP FFC GEN AMK SXT           TEM-1, CTX-M-64                              *qnrS, aac(6\')-Ib-cr*                     *astA, estA*, F4
  JY160522         B2                      Diarrheal pig   ST104      AMP AMC EFT CTX CAZ OTC ENR CIP FFC GEN AMK SXT           TEM-1, CTX-M-64                              *qnrS, aac(6\')-Ib-cr*                     *estA*, F4, F18
  HX160809         B2                      Diarrheal pig   ST127      AMP AMC EFT CTX CAZ CEX ENR CIP FFC OTC GEN AMK SXT       TEM-1, CTX-M-123                             *qnrS*                                     *estB*, F6
  FP170708         B2                      Diarrheal pig   ST127      AMP AMC EFT CTX CEX ENR CIP FFC OTC GEN AMK SXT           CTX-M-123                                    \-                                         *estB*, F5
  JY160503         B2                      Diarrheal pig   ST131      AMP AMC EFT CTX CAZ CEX MEM ENR CIP FFC OTC GEN AMK SXT   CTX-M-9, CTX-M-14, CTX-M-64, KPC-2, OXA-48   *qnrS, qnrB, qnrD, aac(6\')-Ib-cr, qepA*   *elt, estA*, F6
  MX150822         B2                      Diarrheal pig   ST278      AMP AMC EFT CTX CEX ENR CIP FFC OTC GEN AMK SXT           TEM-1, CTX-M-14                              *qnrS*                                     *astA, estB*, F4
  FF170416         B2                      Diarrheal pig   ST355      AMP AMC EFT CTX CAZ CEX ENR CIP FFC OTC GEN AMK SXT       SHV-2, CTX-M-64                              *qnrB*                                     *estA*, F4
  FF170325         B2                      Diarrheal pig   ST372      AMP AMC EFT CTX CAZ CEX ENR CIP FFC OTC GEN AMK SXT       TEM-1, CTX-M-14, CTX-M-15, CTX-M-64          *qnrS, aac(6\')-Ib-cr*                     *estB*, F4, F18
  FF170316         B2                      Diarrheal pig   ST372      AMP AMC EFT CTX CAZ ENR CIP FFC OTC GEN AMK SXT           CTX-M-14, CTX-M-15, CTX-M-123                *qnrS, aac(6\')-Ib-cr*                     *elt, estA*, F4
  MX150923         C                       Diarrheal pig   ST23       AMP AMC CTX CAZ EFT CEX ENR FFC GEN AMK SXT               TEM-1, CTX-M-14                              *qnrS, qnrA*                               *estA, estB*, F18
  MX150814         C                       Diarrheal pig   ST23       AMP AMC EFT CTX CAZ ENR CIP OTC GEN AMK SXT               TEM-1, CTX-M-14                              *qnrB, aac(6\')-Ib-cr*                     *elt*, F4
  ZZ160815         C                       Diarrheal pig   ST23       AMP AMC EFT CTX CAZ CEX ENR CIP FFC OTC GEN SXT           TEM-1, CTX-M-14                              *qnrS*                                     *estA*, F18
  JY160518         D                       Diarrheal pig   ST38       AMP AMC EFT CTX CAZ CEX MEM ENR CIP FFC OTC GEN AMK SXT   TEM-1, CTX-M-15, OXA-48                      *qnrS, qnrA*                               *elt, estB*, F4
  HX160976         D                       Diarrheal pig   ST38       AMP AMC EFT CTX CAZ CEX ENR CIP FFC OTC GEN AMK SXT       CTX-M-9, CTX-M-14                            *qnrA*                                     *elt, estB*, F41
  HX160944         D                       Diarrheal pig   ST38       AMP AMC EFT CTX CAZ CEX ENR CIP FFC OTC GEN AMK SXT       CTX-M-9,CTX-M-14, CTX-M-64                   *qnrB*                                     *elt, astA*, F4
  HX161006         D                       Diarrheal pig   ST69       AMP AMC EFT CTX CAZ CEX ENR CIP FFC OTC GEN AMK SXT       TEM-1, CTX-M-14                              *qnrS, qnrA*                               *astA*, F5
  MX150820         D                       Diarrheal pig   ST405      AMP AMC EFT CTX CAZ CEX MEM ENR CIP FFC OTC GEN AMK SXT   SHV-12, CTX-M-14, CTX-M-15, NDM-1            *qnrB, aac(6\')-Ib-cr*                     *elt, estA*, F4
  LZ161015         D                       Diarrheal pig   ST405      AMP AMC EFT CTX CAZ ENR CIP FFC OTC GEN AMK SXT           SHV-12, CTX-M-15                             *qnrS, qnrB*                               *estB*, F4
  JC160611         D                       Diarrheal pig   ST405      AMP AMC EFT CTX CAZ CEX ENR CIP FFC OTC GEN AMK SXT       TEM-1, CTX-M-9, KPC-2                        *qnrS, qnrB*                               *estB*, F4
  JY160512         D                       Diarrheal pig   ST405      AMP AMC EFT CTX CAZ CEX ENR CIP FFC OTC GEN AMK SXT CLT   TEM-1, CTX-M-9, CTX-M-14, CTX-M-15           *qnrA, qnrD, oqxAB*                        *elt, estA*, F4
  FP170711         D                       Diarrheal pig   ST405      AMP AMC EFT CTX CAZ CEX ENR CIP FFC OTC GEN AMK SXT       TEM-1, SHV-12, CTX-M-15, OXA-48              *aac(6\')-Ib-cr, oqxAB*                    *elt, estB*, F4
  HX170832         D                       Diarrheal pig   ST405      AMP AMC EFT CTX CAZ CEX ENR CIP FFC OTC GEN AMK SXT       TEM-1, SHV-12, CTX-M-15, OXA-48              *aac(6\')-Ib-cr*                           *elt, estB*, F4
  SY160832         D                       Diarrheal pig   ST648      AMP AMC EFT CTX CAZ CEX ENR CIP FFC OTC GEN AMK SXT       SHV-2, CTX-M-9, CTX-M-14, CTX-M-123          *qnrA, aac(6\')-Ib-cr*                     *estB, astA*, F17
  ZZ160908         D                       Diarrheal pig   ST648      AMP AMC EFT CTX CEX ENR CIP FFC OTC GEN AMK SXT           TEM-1, CTX-M-9, CTX-M-14, CTX-M-15           *qnrA*                                     *estB, astA*, F41
  ZZ160917         D                       Diarrheal pig   ST648      AMP AMC EFT CTX CAZ CEX ENR CIP FFC OTC GEN AMK SXT       TEM-1, CTX-M-14, CTX-M-15, CTX-M-64          *qnrS*                                     *estA*, F18
  JY160865         D                       Diarrheal pig   ST648      AMP AMC EFT CTX CAZ CEX ENR CIP FFC OTC GEN AMK SXT       TEM-1, CTX-M-14, CTX-M-15, CTX-M-64          *qnrS*                                     *estB*, F18
  FP170733         E                       Diarrheal pig   ST350      AMP AMC CTX CEX ENR OTC SXT                               CTX-M-9                                      *qnrS*                                     *eae*

*AMP, ampicillin; AMC, amoxicillin-clavulanic acid; EFT, ceftiofur; CTX, cefotaxime; CAZ, ceftazidime; CEX, ceftriaxone; MEM, meropenem; ENR, enrofloxacin; CIP, ciprofloxacin; FFC, florfenicol, OTC, oxytetracycline; GEN, gentamicin; AMK, amikacin; SXT, sulfamethoxazole-trimethoprim; CLT, colistin*.

Characterization of ESBL and PMQR genes
---------------------------------------

Each ESBL producer harbored at least one β-lactamase gene. *bla*~CTX−M~, *bla*~TEM~, *bla*~SHV~, *bla*~OXA−48~, *bla*~KPC−2~, and *bla*~NDM−1~ were detected in forty (90.9%), thirty (68.2%), seven (15.9%), four (9.1%), two (4.5%), and one (2.3%) isolates, respectively (Table [2](#T2){ref-type="table"}). AmpC β-lactamase gene *bla*~CMY−2~ was not detected. Overall, *bla*~CTX−M−14~ (*n* = 24) was the predominant genotype in *bla*~CTX−M~ positive isolates, followed by *bla*~CTX−M−15~ (*n* = 14), *bla*~CTX−M−64~ (*n* = 11), *bla*~CTX−M−9~ (*n* = 10) and *bla*~CTX−M−123~ (*n* = 9), while *bla*~CTX−M−1~ gene was not detected. The distribution of PMQR genes among 44 ESBL-producing *E. coli* isolates is shown in Table [2](#T2){ref-type="table"}. 88.6% (39/44) of ESBL producers were found to harbor at least one PMQR gene, and seven types of PMQR were identified. *qnrS, qnrA, aac(6\')-Ib-cr, qnrB, oqxAB, qnrD*, and *qepA* were detected alone or incombination in 52.3% (24/44), 34.1% (15/44), 27.3% (12/44), 20.5% (9/44), 6.8% (3/44), 4.5% (2/44), and 4.5% (2/44) of ESBL-producing isolates, respectively. *qnrS* was the most common PMQR gene, and *qnrS*+*qnrA* was the most common combination (*n* = 6). No isolates were positive for *qnrC* gene. Among 39 PMQR positive isolates, 28 (80%) isolates were positive for more than one PMQR determinant. Furthermore, all PMQR genes were detected in co-existence with β-lactamases, and one isolate from the intestinal content of a 15-day-old dead piglet with serious diarrhea harbored β-lactamase genes *bla*~TEM~, *bla*~SHV~, *bla*~CTX−M−9~, *bla*~CTX−M−14~, *bla*~CTX−M−64~ and carbapenemase gene *bla*~OXA−48~ and *bla*~KPC−2~, as well as PMQR genes *qnrS, qnrB, qnrD, qepA*, and *aac(6\')-Ib-cr*. *bla*~OXA−48~ gene was detected in four meropenem-non-susceptible or meropenem-resistant isolates.

Conjugation experiments
-----------------------

Five out of eight ESBL producers successfully transferred the β-lactamase genes to recipient strain *E. coli* J53 AZ^r^. PCR analysis showed that the presence of respective β-lactamase genes, including one *bla*~OXA−48~-carrying plasmids from all transconjugants. Accordingly, PMQR genes *qnr* and *aac-(6*′*)-Ib-cr* were co-transferred with β-lactamase genes (Table [3](#T3){ref-type="table"}). Antimicrobial susceptibility patterns showed that all donors and their transconjugants were resistant to amoxicillin-clavulanic acid, ampicillin, ceftiofur, cefotaxime, and all transconjugants exhibited an increase of at least 8-fold in MICs compared to the recipient, *E. coli* J53 AZ^r^. The enrofloxacin MICs for four transconjugants harboring *aac-(6*′*)-Ib-cr* ranged from 0.125 to 0.5 mg/L, representing an increase of 4-fold to 8-fold compared with the recipient (Table [3](#T3){ref-type="table"}). Additionally, the transconjugants remained susceptible to meropenem, enrofloxacin, florfenicol, oxytetracycline, gentamicin, sulfamethoxazole-trimethoprim and colistin, whereas one *bla*~OXA−48~ positive transconjugant reduced meropenem susceptibility.

###### 

Antimicrobial susceptibility profiles of extended-spectrum β-lactamase-producing *E. coli* isolates used in the conjugation experiments.

  **Isolates**         **MIC (**μ**g/ml) of antimicrobials**                                                **Presence or absence of**                                                                              
  -------------------- --------------------------------------- ---- ------- ------- ------- ------- ------- ---------------------------- ------- ------- ------- ------- ------- ---- ---- ---- ---- ---- ---- ---- ----
  **DONORS**                                                                                                                                                                                                        
  JY160503             512                                     32   64      32      64      32      8       128                          64      128     32      128     0.063                  \+   \+   \+   \+   \+
  JY160512             256                                     32   64      32      128     8       0.03    64                           128     64      32      256     4       \+        \+   \+   \+        \+   
  FP170711             256                                     64   64      64      256     32      16      128                          128     64      64      256     0.125   \+   \+   \+             \+        \+
  ZZ160908             256                                     64   128     128     1       64      0.063   128                          64      128     32      128     0.125   \+        \+   \+   \+        \+   
  MX150820             256                                     32   64      16      2       32      4       256                          64      64      64      128     0.25         \+   \+   \+             \+   \+
  Recipient J53AZ^r^   4                                       1    0.125   0.125   0.063   0.063   0.015   0.063                        0.063   0.25    0.25    0.063   0.03                                       
  **TRANSFORMANTS**                                                                                                                                                                                                 
  Trans-JY160503       256                                     64   64      16      64      32      0.5     0.5                          0.063   0.125   0.125   0.125   0.03                   \+   \+        \+   \+
  Trans-JY160512       256                                     32   32      32      128     4       0.03    0.25                         0.125   0.5     0.25    0.125   0.063   \+        \+   \+   \+        \+   
  Trans-FP170711       128                                     32   64      16      128     2       0.5     0.125                        0.063   0.5     0.25    0.25    0.03    \+   \+                  \+        \+
  Trans-ZZ160908       256                                     32   128     64      0.5     16      0.03    0.25                         0.03    0.25    0.5     0.063   0.03    \+        \+   \+   \+        \+   
  Trans-MX150820       128                                     32   64      16      0.5     32      0.03    0.5                          0.03    0.125   0.125   0.063   0.063        \+   \+   \+                  \+

MLST profiles
-------------

Forty-four ESBL producers belonged to 24 sequence types (STs) (Table [2](#T2){ref-type="table"}). The most prevalent was ST405 (*n* = 6), followed by ST10 (*n* = 5). ST405 (*n* = 6), ST648 (*n* = 4) and ST38 (*n* = 3) of phylogenetic group D accounted for 29.5% of the ESBL producers. The carbapenemases *bla*~OXA−48~, *bla*~NDM−1~ and *bla*~KPC−2~ were connected with sequence types ST405, ST131 and ST38. The isolates with same STs have similar virotypes and β-lactamase profiles.

Discussion {#s4}
==========

The prevalence of ESBL-producing *E. coli* isolates in food animals has been increasing worldwide (Liebana et al., [@B17]). In China, diarrhea caused by pathogenic *E. coli*, especially ESBL-producing *E. coli* poses a serious threat to the swine industry and public health (Lei et al., [@B16]; Xu et al., [@B44]). The present study is the first contribution to explore the detailed characterizations of ESBL-producing *E. coli* isolates from pigs in Northwest China. Forty-four (9.6%) isolates were confirmed as ESBL producers, while it is noteworthy that 456 *E. coli* in this study isolated from feces of healthy and diarrheal pigs, and the prevalence of ESBL producer were significantly higher among isolates from diarrheal pigs than that form healthy isolates (20.4vs. 2.2%; *P* \< 0.001). The detectable rate of ESBL producer in diarrheal pigs was similar with the result in Sichuan (26.8%), a neighbor province of Shaanxi, while it was significantly lower than in Heilongjiang (43.2%), a province in the northeast China (Tian et al., [@B36]; Xu et al., [@B44]). Moreover, our results showed that ESBL producers mainly belonged to phylogenetic groups D and B2, and to a lesser extent to phylogenetic A, while the previous studies showed that *E. coli* from pigs or duck in China also mainly fell into phylogenetic groups A (Wang et al., [@B39]; Ma et al., [@B24]). It is further confirmed that the emergence of ESBL-producing *E. coli* has a geographic variation with respect to demographic, environmental, behavioral, socioeconomic and infectious risk factors with the extending of ESBL-producing isolates stage by stage.

All 456 *E. coli* isolates in this study were tested for their susceptibility to 15 antimicrobial agents. Overall, the number of resistant isolates in ESBL producers and isolates from diarrheal pigs were higher than that from healthy pigs (*P* \> 0.001). It is suggested that the isolates from diarrheal pigs may be more likely to develop antibiotic resistance than that from healthy pigs because of the frequent use of antimicrobials in preventing and treating diarrhea. All ESBL producers were resistant to at least five antimicrobial agents, and vast majority of them (\>93%) remained susceptible to meropenem and colistin, which are considered the effective candidates for treatment of serious infections caused by *E. coli* in pig farms of China. According to the virotypes, 86.4% of ESBL producers carried both enterotoxins and fimbrial adhesins. It is indicated that these isolates should be enterotoxigenic *E. coli* (ETEC), which are responsible for neonatal diarrhea and postweaning diarrhea in piglets. F4 fimbrial adhesin was present 40.9% of the ESBL producers, it is consistent with the previous studies that F4 adhesin gene is one of the most frequently found genes in *E. coli* isolates from suckling and weaning piglets (Vu Khac et al., [@B38]; Zhang et al., [@B46]). Furthermore, the gene combinations of F4+*estA*/*estB* were present in 34.1% of the isolates.

Since the early 2000s, CTX-M-type ESBLs have been increasingly reported, and they have now replaced TEM and SHV as the most common type of ESBL (Barguigua et al., [@B3]). The most predominant ESBL gene in this study was *bla*~CTX−M~ (90.9%), and the similar findings showed that CTX-Ms accounted for 87.1% of ESBL-producing *E. coli* isolated from food animals based on a previous survey in China (Rao et al., [@B29]). *bla*~CTX−M−14~ remained the most common genotype, and followed by *bla*~CTX−M−15~. It is surprising that no isolate contained *bla*~CTX−M−1~, whereas it was detected in the ESBL-producing *E. coli* from dogs, retail pork and water bodies in Shaanxi province (Xi et al., [@B43]; Liu et al., [@B21]). In regards to the linkage of phylogenetic group and β-lactamases, isolates of group D harbored more β-lactamases genes, and isolates of group A harbored less β-lactamases. Novel hybrid β-lactamase gene *bla*~CTX−M−123~ was firstly discovered in *E. coli* from pig feces in China in 2013 (He et al., [@B12]), and it was detected in nine ESBL producers in this study. Moreover, four ESBL producers were commensal isolates from healthy pigs, it was further indicated that some commensal organisms in animals have acquired β-lactamase genes with the increasing use of β-lactams in animals. *bla*~OXA−48~ was detected in four ESBL producers from diarrheal pigs. As a globally emerging carbapenemase gene, *bla*~OXA−48~ could hydrolyze carbapenems and β-lactamase inhibitors but has no activity toward broad-spectrum cephalosporins (Mathers et al., [@B25]). *bla*~OXA−48~ was firstly discovered in *E. coli* from dogs in Germany in 2013, and afterward it was reported in *E. coli* from companion animals in the United States in 2016 (Stolle et al., [@B32]; Liu et al., [@B23]). In 2017, it was reported in pigs in Italy (Pulss et al., [@B28]). Most recently, it was detected in *Enterobacteriaceae* from river water in Algeria (Tafoukt et al., [@B34]). Considering the importance of *bla*~OXA−48~ gene in public health, it is necessary to further investigate the dissemination of *bla*~OXA−48~ producing *E. coli* isolates among different sources.

PMQR genes were often found to be strongly associated with β-lactamase genes and even in the same plasmid, and they are not merely able to confer resistance against quinolones but also often related to ESBLs (Jeong et al., [@B14]). In this study, PMQR genes were present in 88.6% of ESBL producers, and the similar findings have been reported in ESBL-producing *E. coli* isolates form pigs in previous studies in China by Xu et al. (87.4%) and Liu et al (83.8%) (Liu et al., [@B18]; Xu et al., [@B44]). Thirty-seven ESBL producers (84.1%) harbored at least one *qnr* gene, and *qnrS* was the predominant, whereas a low prevalence of *qnr* genes was detected among ESBL-producing *E. coli* isolates in France and Canada (1.6 and 1%, respectively). In addition, *qepA* gene was detected in combination with other PMQR and β-lactamase genes in four isolates (10%). The frequent combination of β-lactamases and PMQRs in this study further supported the previous studies that coproduction of β-lactamase and PMQR genes could contribute to the dissemination of MDR isolates, and also reflect the fact that genes encoding resistance to β-lactams and quinolones are located on the same plasmid.

Twenty-four different sequence types were identified, and three sequence types (ST405, ST10, and ST648) accounted for 34.1% of the ESBL producers. Sequence types ST10, ST38, ST131, ST648, and ST405 clones were documented in different sources according to MLST databases, and could favor the dissemination of CTX-M worldwide among *E. coli* isolates (Hernandez and Gonzalez-Acuna, [@B13]). In the present study, a few isolates belonging to different STs shared similar β-lactamase and PMQR gene profiles, whereas several isolates belonging to same ST exhibited different gene profiles. The similar results were observed among *E. coli* isolates from dogs and cats in previous studies (Liu et al., [@B23],[@B21]). The possible explanation is that the pig trade, personnel exchanges and water sources among adjacent regions may lead to the dissemination of isolates with same gene profiles or same ST types. Anyway, deeper analyses for such isolates are necessary in the future. It is noteworthy that *bla*~OXA−48~ gene were detected in four isolates with reduced susceptibility or resistance to meropenem. The *bla*~OXA−48~ positive isolates co-harbored variants of β-lactamase genes, and they also were associated with sequence types ST38, ST405, and ST131. Additionally, *bla*~OXA−48~ positive *E. coli* clone ST38 had been previously reported in France, Germany and Algeria (Poirel et al., [@B27]; Kaase et al., [@B15]; Bouaziz et al., [@B5]). In the current study, we firstly reported the occurrence of *bla*~OXA−48~ positive *E. coli* clone ST38 from a sucking piglet with diarrhea in Shaanxi. Clone ST38 has achieved notoriety as it is now rapidly and globally disseminated, and its potential to serve as a vehicle for spread of carbapenemases is profoundly alarming. *bla*~NDM−1~ producing *E. coli* isolate, emerging as a public health threat, has gained global attention as it could hydrolyze almost all β-lactams with the exception of aztreonam (Nordmann et al., [@B26]), and it has previously been detected in *E. coli* isolates from pigs (Fischer et al., [@B10]). Our results revealed that *bla*~NDM−1~ and other β-lactamase genes coexisted in one isolates, it is a potential public health concern as the pig carrying *bla*~NDM−1~ and other β-lactamase genes may enter the food chain.

Conclusion {#s5}
==========

In conclusion, all ESBL-producing *E. coli* isolates both from healthy and diarrheal pigs in Northwest China exhibited MDR phenotype. The *bla*~CTX−M−14~ and *qnrS* were the predominant β-lactamase gene and PMQR gene in ESBL producers, respectively. *estA* and F4 were the most prevalent enterotoxin and fimbrial adhesin, respectively. One ST131 isolate harbored β-lactamase genes *bla*~TEM~, *bla*~SHV~, *bla*~CTX−M−9~, *bla*~CTX−M−14~, *bla*~CTX−M−64~, and carbapenemase genes *bla*~OXA−48~ and *bla*~KPC−2~, as well as PMQR genes *qnrS, qnrB, qnrD, qepA* and *aac(6\')-Ib-cr*. The findings could provide useful information for a national monitoring of antimicrobial resistance in bacteria from food animals in China.
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